Trends in the use of postprostatectomy therapies for patients with prostate cancer: A surveillance, epidemiology, and end results medicare analysis

Cancer

Volumn 119, Issue 18, 2013, Pages 3295-3301

  Sheets, Nathan C ^a   Hendrix, Laura H ^a   Allen, Ian M ^a,b   Chen, Ronald C ^a,c  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

adjuvant therapy; androgen deprivation therapy; prostate cancer; prostatectomy; radiotherapy

Indexed keywords

AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; POPULATION DENSITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREND STUDY; TUMOR CLASSIFICATION;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; PROSTATE CANCER; PROSTATECTOMY; RADIOTHERAPY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; MALE; MEDICARE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84883600392     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28222     Document Type: Conference Paper

References (25)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA,. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002; 20: 3376-3385.
3. Patel AR, Stephenson AJ,. Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage? Nat Rev Urol. 2011; 8: 385-392.
4. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009; 27: 2924-2930.
5. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005; 366: 572-578. (Pubitemid 41140332)
6. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006; 296: 2329-2335. (Pubitemid 44749360)
7. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D,. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17: 584-590. (Pubitemid 47096709)
8. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009; 181: 956-962.
9. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology 2012: prostate cancer. nccn.org/professionals/physician-gls/pdf/ prostate.pdf. Accessed June 22, 2012.
10. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD,. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;(4): CD006019.
11. Hoffman KE, Nguyen PL, Chen MH, et al. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011; 185: 116-120.
12. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004; 291: 1325-1332. (Pubitemid 38541647)
13. Bolla M, Collette L,. pT3N0M0 prostate cancer: a plea for adjuvant radiation. Nat Rev Urol. 2009; 6: 410-412.
14. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy versus observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299: 2760-2769. (Pubitemid 351846851)
15. Williams SB, Gu X, Lipsitz SR, Nguyen PL, Choueiri TK, Hu JC,. Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer. 2011; 117: 4846-4854.
16. Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ,. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer. 2012; 118: 333-341.
17. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL,. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002; 40 (suppl 8): IV-43-IV-48.
18. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J,. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002; 40 (suppl 8): IV-49-IV-54.
19. Grol R, Grimshaw J,. From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003; 362: 1225-1230. (Pubitemid 37255352)
20. Gotzsche PC, Olsen O,. Is screening for breast cancer with mammography justifiable? Lancet. 2000; 355: 129-134. (Pubitemid 30068564)
21. Mauermann J, Fradet V, Lacombe L, et al. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients [published online ahead of print August 10, 2012 ]. Eur Urol.
22. Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011; 29: 2040-2045.
23. Shipley WU, Hunt D, Lukka H, et al. Initial report of RTOG 9601: a phase III trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease, and elevated PSA levels. Int J Radiat Oncol Biol Phys. 2010; 78: S27.
24. Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P,. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011; 60: 554-563.
25. Moinpour CM, Hayden KA, Unger JM, et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008; 26: 112-120.